Vascular access for hemodialysis patients: New data should guide decision making

Academic Article

Abstract

  • © 2019 by the American Society of Nephrology. This commentary critically examines key assumptions and recommendations in the 2006 Kidney DiseaseOutcomes Quality Initiative vascular access guidelines, and argues that several are not relevant to the contemporary United States hemodialysis population. First, the guidelines prefer arteriovenous fistulas (AVFs) over arteriovenous grafts (AVGs), on the basis of their superior secondary survival and lower frequency of interventions and infections. However, intent-to-treat analyses that incorporate the higher primary failure of AVFs, demonstrate equivalent secondary survival of both access types.Moreover, the lower rate of AVF versus AVG infections is counter balanced by the higher rate of catheter-related bloodstream infections before AVF maturation. In addition,AVFswithassisted maturation (interventions before successful AVF use), which account for about 50%of new AVFs, are associated with inferior secondary patency compared with AVGs without intervention before successful use. Second, the guidelines posit lower access management costs for AVFs than AVGs. However, in patients who undergo AVF or AVG placement after starting dialysis with a central venous catheter (CVC), the overall cost of accessmanagement is actually higher in patients receiving an AVF. Third, the guidelines prefer forearmover upper arm AVFs. However, published data demonstrate superior maturation of upper arm versus forearm AVFs, likely explaining the progressive increase in upper arm AVFs in the United States. Fourth, AVFs are thought to fail primarily because of aggressive juxta-anastomotic stenosis. However, recent evidence suggests that many AVFs mature despite neointimal hyperplasia, and that suboptimal arterial vasodilationmay be an equally important contributor to AVF nonmaturation. Finally, CVC use is believed to result in excess mortality in patients on hemodialysis. However, recent data suggest that CVC use is simply a surrogate marker of sicker patients who are more likely to die, rather than being a mediator of mortality.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Allon M
  • Start Page

  • 954
  • End Page

  • 961
  • Volume

  • 14
  • Issue

  • 6